Interaction between tacrolimus and omeprazole in a pediatric liver transplant recipient [1]

Transplantation

Volumn 81, Issue 3, 2006, Pages 487-488

  Moreau, Céline ^a   Taburet, Anne Marie ^a   Furlan, Valérie ^a   Debray, Dominique ^a   Loriot, Marie Anne ^b  

^a BICÊTRE HOSPITAL   (France)

^b Medical University   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ACEBUTOLOL; ACETYLSALICYLIC ACID; COTRIMOXAZOLE; CYTOCHROME P450 3A4; METHYLPREDNISOLONE; NIFEDIPINE; OMEPRAZOLE; TACROLIMUS; VALACICLOVIR;

ABSENCE OF SIDE EFFECTS; ADOLESCENT; ANAMNESIS; CASE REPORT; CLINICAL FEATURE; DRUG BLOOD LEVEL; GASTROESOPHAGEAL REFLUX; HUMAN; INTRAHEPATIC CHOLESTASIS; LETTER; LIVER FUNCTION; LIVER GRAFT REJECTION; LIVER TRANSPLANTATION; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL;

ADOLESCENT; ANTI-ULCER AGENTS; CYTOCHROME P-450 ENZYME SYSTEM; DRUG INTERACTIONS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LIVER TRANSPLANTATION; MALE; OMEPRAZOLE; TACROLIMUS;

EID: 32844455043     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.tp.0000194861.59543.b9     Document Type: Letter

References (17)

1. Kaufman SS, Lyden ER, Brown CR, et al. Omeprazole therapy in pediatric patients after liver and intestinal transplantation. J Pediatr Gastroenterol Nutr 2002; 34(2): 194.
2. Renberg L, Simonsson R, Hoffmann KJ. Identification of two main urinary metabolites of [14C]omeprazole in humans. Drug Metab Dispos 1989; 17(1): 69.
3. Andersson T, Miners JO, Veronese ME, et al. Identification ot human liver cytochrome P450 isoforms mediating omeprazole metabolism. Br J Clin Pharmacol 1993; 36(6): 521.
4. Bottiger Y, Tybring G, Gotharson E, Bertilsson L. Inhibition of the sulfoxidation of omeprazole by ketoconazole in poor and extensive metabolizers of S-mephenytoin. Clin Pharmacol Ther 1997; 62(4): 384.
5. Grenier FC, Luczkiw J, Bergmann M, et al. A whole blood FK 506 assay for the IMx analyzer. Transplant Proc 1991; 23 (6): 2748.
6. van Gelder T. Drug interactions with tacrolimus. Drug Saf 2002; 25(10): 707.
7. Christians U, Schmidt G, Bader A, et al. Identification of drugs inhibiting the in vitro metabolism of tacrolimus by human liver microsomes. Br J Clin Pharmacol 1996; 41(3): 187.
8. Matsuda H, Iwasaki K, Shiraga T, et al. Interactions of FK506 (tacrolimus) with clinically important drugs. Res Commun Mol Pathol Pharmacol 1996; 91(1): 57.
9. Kita T, Sakaeda T, Aoyama N, et al. Optimal dose of omeprazole for CYP2C19 extensive metabolizers in anti-Helicobacter pylori therapy: pharmacokinetic considerations. Biol Pharm Bull 2002; 25(7): 923.
10. Rost KL, Roots I. Nonlinear kinetics after high-dose omeprazole caused by saturation of genetically variable CYP2C19. Hepatology 1996; 23(6): 1491.
11. Yamazaki H, Inoue K, Shaw PM, et al. Different contributions of cytochrome P450 2C19 and 3A4 in the oxidation of omeprazole by human liver microsomes: effects of contents of these two forms in individual human samples. J Pharmacol Exp Ther 1997; 283(2): 434.
12. Takahashi K, Motohashi H, Yonezawa A, et al. Lansoprazole-tacrolimus interaction in Japanese transplant recipient with CYP2C19 polymorphism. Ann Pharmacother 2004; 38(5): 791.
13. Itagaki F, Homma M, Yuzawa K, et al. Drug interaction of tacrolimus and proton pump inhibitors in renal transplant recipients with CYP2C19 gene mutation. Transplant Proc 2002; 34(7): 2777.
14. Lampen A, Christians U, Guengerich FP, et al. Metabolism of the immunosuppressant tacrolimus in the small intestine: cytochrome P450, drug interactions, and interin-dividual variability. Drug Metab Dispos 1995; 23(12): 1315.
15. Lindell M, Karlsson MO, Lennernas H, et al. Variable expression of CYP and Pgp genes in the human small intestine. Eur J Clin Invest 2003; 33(6): 493.
16. Christians U, Jacobsen W, Benet LZ, Lampen A. Mechanisms of clinically relevant drug interactions associated with tacrolimus. Clin Pharmacokinet 2002; 41(11): 813.
17. Sipe BE, Jones RJ, Bokhart GH. Rhabdomyolysis causing AV blockade due to possible atorvastatin, esomeprazole, and clarithromycin interaction. Ann Pharmacother 2003; 37(6): 808.